Glycolysis inhibition from the outset is the optimum solution for reliable diagnosis of diabetes diseases

Kremsmünster, March 23rd, 2016

The rapid breakdown of glucose (glycolysis) in venous blood samples is very significant for the diagnosis of both diabetes mellitus and gestational diabetes. Greiner Bio-One now has the optimum solution in the form of the new VACUETTE® FC Mix tube.

 

Diabetes mellitus is on the increase. It is a group of metabolic disorders, the common feature of which is a chronically elevated blood sugar level (1). However it is not only diabetes mellitus but also gestational diabetes (GDM), the most common disease during pregnancy, which is becoming increasingly important. The aim is to detect/rule out gestational diabetes at an early stage. If not identified, GDM can lead to complications such as infections, premature births and long-term effects for the mother and child (2).

In order to have a reliable diagnosis, it is necessary to inhibit glucose breakdown immediately after collecting blood. Various institutions such as the DDG*/DGGG** and the ADA*** have drafted guidelines (3),(4), which recommend the addition of a citrate-fluoride additive to maintain the "in vivo glucose level".

The special feature of the new VACUETTE® FC Mix tube from Greiner Bio-One is the powder additive. It stabilises the glucose level immediately after collection for 48 hours. This allows for reliable diagnosis of diabetes conditions and avoids false negative analysis results. The stabilisation is carried out in the whole blood and therefore does not require immediate centrifugation. Unlike in tubes where liquid is added, the finely granulated additive does not cause a dilution effect. There is no need to convert the measurement result.

How does the additive work in the new VACUETTE® FC Mix tube?

The citrate/citric acid buffer reduces the pH value in the sample. As a result, enzymes needed for the glycolysis process are inhibited and the actual "in vivo level" is stabilised from the start. The additive is completely dissolved, and therefore optimally mixed with the sample, after swivelling ten times. In the case of storage between 4°C and room temperature, a further sodium fluoride additive ensures long-term stabilisation for 48 hours. 

The VACUETTE® FC Mix tube is available with both a grey and pink security cap and therefore allows for differentiation from standard glucose tubes. The cap is particularly easy to open and allows for hygienic working in the laboratory. The VACUETTE® FC Mix tube is made of highly-transparent PET plastic and is shatter-proof.

Extensive study material on the VACUETTE® FC Mix tube can be found on our homepage via the following link:

Stability of glucose concentrating using VACUETTE® FC Mix blood collection tubes

Suitability of VACUETTE® FC Mix blood collection tubes for gestational diabetes testing

Brochure

Please Download the Brochure here...

The VACUETTE® FC Mix tube is currently not available for USA.

Sources:

Sirid Griebenow (2016): Suitability of VACUETTE® FC Mix Blood Collection Tube for gestational diabetes testing, Whitepaper Hospital Isala, Zwolle (NL)

Sirid Griebenow (2015): Stability of glucose concentration using VACUETTE® FC Mix blood collection tubes, Internal Study by GBO

  1. Griebler et al (2013): Zivilisationskrankheit Diabetes: Ausprägungen – Lösungsansätze – Herausforderungen. [Lifestyle disease diabetes: characteristics – possible solutions – challenges]. Österreichischer Diabetesbericht [Austrian Diabetes Report] 2013. Vienna: Federal Ministry of Health
  2. Deutsche Diabetes Gesellschaft (DDG), Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG): Gestationsdiabetes mellitus (GDM) – Evidenzbasierte Leitlinie zu Diagnostik, Therapie und Nachsorge; Klasse S3 [Gestational diabetes mellitus (GDM) – Evidence-based guidelines for diagnostics, treatment and after-care, class S3]. AWMF register no: 057/008; as of: 31/08/2011, valid until: 31/08/2016
  3. Kellerer et al (2011), Gestationsdiabetes mellitus – Praxisleitlinie der DDG und der DGGG [Gestational diabetes mellitus – practice guidelines of the DDG and DGGG] 
  4. Sacks et al (2011), Guidelines and Recommendations of Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus, ClinicaChemistry 57:6

*   Deutsche Diabetes Gesellschaft (German Diabetes Society)

**  Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (German Society for Gynaecology and Obstetrics)

***American Diabetes Association